Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...

Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, ...

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...

A new type of antibody which stimulates the immune system to target cancer cells slows tumour growth, according to new research.

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

HER2 positive cancers more likely to respond to treatment that specifically attacks the HER2 protein. Alternatively, if you have lower amounts of the HER2 protein, your cancer is HER2 negative.

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...

IBC is a rare, aggressive breast cancer with higher rates in younger women and those of African descent, requiring a ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...